Abbott Labs (NYSE:ABT) has always been a little different as a medical technology company, with a history of zigging when other companies zag. For now, that somewhat contrarian philosophy is paying off, as Abbott is one of the very few large-cap medical technology companies to be showing any meaningful growth.

IN PICTURES: 9 Simple Investing Ratios You Need To Know

The Quarter That Was
Abbott came through with 12% revenue growth in the third quarter (or 13% if foreign currency effects are reversed). Pharmaceuticals is still overwhelmingly the largest business at Abbott, and this unit grew more than 23% due in large part to the acquisition of Solvay. Without this deal, growth was probably in the very low single-digits. Elsewhere, the nutritional business was disappointing (down more than 2%) due to a recall, while the diagnostics business was basically on target (up about 2%), and the vascular business was strong (up almost 20%).

On an adjusted basis, the company also delivered strong profitability. Gross margin (again, adjusted) rose 4.5 points to almost 62%, while adjusted earnings grew about 14% for the quarter.

The Road Ahead
Abbott has spent a lot of its history as a med-tech chameleon - often a just a bit below the radar of most investors and willing to change its business model in anticipation of future market developments. For instance, the analyst community was not necessarily overjoyed about the company's decision to expand into drug-coated stents years ago, but now Abbott is the player with all of the momentum in that lucrative niche, and Boston Scientific (NYSE:BSX) and Medtronic (NYSE:MDT) are on their heels. Likewise, while Beckman Coulter (NYSE:BEC), Roche (Nasdaq:RHHBY) and Becton Dickinson (NYSE:BDX) are all involved in molecular diagnostics, Abbott may steal the march on them.

Looking ahead, it would seem that Abbott is where it needs to be with its pharmaceutical business. The company has established a foothold in generics, following the lead of major players like Novartis (NYSE:NVS), and has a solid emerging pipeline in oncology and neurology. So while there is some threat to the company's immunology business from Pfizer (NYSE:PFE) and Incyte (Nasdaq:INCY), Abbott does not seem to need to do a deal - and given the FDA's attitude to new drug approvals, Abbott might be better-shielded from competitors than the market expects. (For more, see Top-Heavy Pharmaceuticals.)

If Abbott needs to do anything, it may be in the diagnostics and device franchises. An acquisition or two (like, say, of Cepheid (Nasdaq:CPHD)) could accelerate the development time lines, and the company has the luxury of cherry-picking promising areas of medical devices for future growth.

The Bottom Line
Although Abbott's stock is closer to its high than its low, the stock has actually been an underperformer relative to the S&P 500. As a strong candidate for best-of-breed within healthcare, though, it could be due for some appreciation. The stock is not necessarily cheap by fundamental indicators like EV/revenue or EV/EBITDA (or P/E-based metrics), but looks about 30% undervalued by cash flow. Abbott's stock is not likely to ever be scintillating, and the company will make moves that leave people scratching their heads in the short term, but this could be a long-term winner for patient investors. (For more, see The Characteristics Of A Successful Company.)

Use the Investopedia Stock Simulator to trade the stocks mentioned in this stock analysis, risk free!

Related Articles
  1. Investing News

    Latest Labor Numbers: Good News for the Market?

    Some economic numbers are indicating that the labor market is outperforming the stock market. Should investors be bullish?
  2. Investing News

    Stocks with Big Dividend Yields: 'It's a Trap!'

    Should you seek high yielding-dividend stocks in the current investment environment?
  3. Investing News

    Should You Be Betting with Buffett Right Now?

    Following Warren Buffett's stock picks has historically been a good strategy. Is considering his biggest holdings in 2016 a good idea?
  4. Products and Investments

    Cash vs. Stocks: How to Decide Which is Best

    Is it better to keep your money in cash or is a down market a good time to buy stocks at a lower cost?
  5. Investing News

    Who Does Cheap Oil Benefit? See This Stock (DG)

    Cheap oil won't benefit most companies, but this retailer might buck that trend.
  6. Investing

    How to Ballast a Portfolio with Bonds

    If January and early February performance is any guide, there’s a new normal in financial markets today: Heightened volatility.
  7. Stock Analysis

    Performance Review: Emerging Markets Equities in 2015

    Find out why emerging markets struggled in 2015 and why a half-decade long trend of poor returns is proving optimistic growth investors wrong.
  8. Investing

    Don't Freak Out Over Black Swans; Be Prepared

    Could 2016 be a big year for black swans? Who knows? Here's what black swans are, how they can devastate the unprepared, and how the prepared can emerge unscathed.
  9. Investing News

    Today's Sell-off: Are We in a Margin Liquidation?

    If we're in market liquidation, is it good news or bad news? That party depends on your timeframe.
  10. Investing News

    Bank Stocks: Time to Buy or Avoid? (WFC, JPM, C)

    Bank stocks have been pounded. Is this the right time to buy or should they be avoided?
RELATED FAQS
  1. When does a growth stock turn into a value opportunity?

    A growth stock turns into a value opportunity when it trades at a reasonable multiple of the company's earnings per share ... Read Full Answer >>
  2. What is the formula for calculating EBITDA?

    When analyzing financial fitness, corporate accountants and investors alike closely examine a company's financial statements ... Read Full Answer >>
  3. How do I calculate the P/E ratio of a company?

    The price-earnings ratio (P/E ratio) is a valuation measure that compares the level of stock prices to the level of corporate ... Read Full Answer >>
  4. How do you calculate return on equity (ROE)?

    Return on equity (ROE) is a ratio that provides investors insight into how efficiently a company (or more specifically, its ... Read Full Answer >>
  5. How do you calculate working capital?

    Working capital represents the difference between a firm’s current assets and current liabilities. The challenge can be determining ... Read Full Answer >>
  6. What is the formula for calculating the current ratio?

    The current ratio is a financial ratio that investors and analysts use to examine the liquidity of a company and its ability ... Read Full Answer >>
COMPANIES IN THIS ARTICLE
Trading Center